Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Isradipine improves platelet function in hypertensives.

H Sinzinger1, I Virgolini, F Rauscha

  • 1Wilhelm Auerswald-Atherosclerosis Research Group (ASF), University of Vienna, Austria.

European Journal of Clinical Pharmacology
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Compromising bradycardia: management in the emergency department.

Resuscitation·2007
Same author

Natriuretic peptides and the prevalence of congestive heart failure in patients with pacemakers.

European journal of clinical investigation·2004
Same author

Diagnostic value of onset-recordings and marker annotations in dual chamber pacemaker stored electrograms.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2002
Same author

[Pacemaker dysfunction in the clinical practice].

Wiener klinische Wochenschrift·2001
Same author

Modified LDL decreases the binding of prostaglandin E2, I2, and E1 onto monocytes in patients with peripheral vascular disease.

Arteriosclerosis, thrombosis, and vascular biology·1997
Same author

Assessment of myocardial injury by serum tumour necrosis factor alpha measurements in acute myocardial infarction.

European heart journal·1996
Same journal

Efficacy and safety of Ensitrelvir in COVID-19 patients: a systematic review and meta-analysis with focus on viral clearance and RNA change.

European journal of clinical pharmacology·2026
Same journal

Comparing National Health Technology Assessment approaches and the new European Joint Clinical Assessment framework: The case of onco-hematological medicines.

European journal of clinical pharmacology·2026
Same journal

The efficacy of letrozole in the medical management of ectopic pregnancy: a systematic review and meta-analysis.

European journal of clinical pharmacology·2026
Same journal

Detection of intravenous drug physicochemical incompatibilities in clinical practice: e-Harvis compared to reference tools.

European journal of clinical pharmacology·2026
Same journal

Efficacy and safety of doravirine/islatravir for the treatment of HIV-1: a systematic review and meta-analysis of randomized controlled trials with GRADE assessment.

European journal of clinical pharmacology·2026
Same journal

Critical analysis of digitalis glycosides: declining use but increasing poison-center exposure cases for digitoxin.

European journal of clinical pharmacology·2026
See all related articles

Isradipine treatment effectively lowered blood pressure and inhibited platelet activation in hypertensive patients. This suggests potential benefits for managing hypertension by addressing both blood pressure and platelet function.

Area of Science:

  • Cardiovascular pharmacology
  • Hematology

Background:

  • Hypertension is a major risk factor for cardiovascular disease.
  • Platelet activation plays a significant role in thrombotic events associated with hypertension.

Purpose of the Study:

  • To investigate the effects of isradipine on ex vivo platelet function in male hypertensive patients.
  • To assess the impact of isradipine on blood pressure and platelet aggregation markers.

Main Methods:

  • 10 male hypertensive patients received isradipine (1.25 mg BID for 4 weeks, then 2.5 mg BID for 4 weeks).
  • Measurements included blood pressure, platelet aggregation (ADP-induced), serum thromboxane B2, and beta-thromboglobulin at rest and during/after exercise.
  • Platelet count and 6-oxo-prostaglandin F1 alpha levels were also assessed.

Related Experiment Videos

Main Results:

  • Isradipine significantly reduced systolic and diastolic blood pressure.
  • Platelet aggregation, serum thromboxane B2, and beta-thromboglobulin levels were significantly decreased.
  • Platelet count and 6-oxo-prostaglandin F1 alpha levels remained unaffected.

Conclusions:

  • Isradipine effectively lowers blood pressure in hypertensive patients.
  • The drug demonstrates inhibitory effects on platelet activation, reducing key markers.
  • Combined blood pressure reduction and platelet inhibition suggest potential clinical utility in hypertension management.